My Application Form Status

Check the status of your application form with Angel Broking.
Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Jindal Drilling & Industries standalone net profit declines 3.66% in the June 2016 quarter

Sep 14,2016

Net profit of Jindal Drilling & Industries declined 3.66% to Rs 9.48 crore in the quarter ended June 2016 as against Rs 9.84 crore during the previous quarter ended June 2015. Sales rose 11.24% to Rs 92.66 crore in the quarter ended June 2016 as against Rs 83.30 crore during the previous quarter ended June 2015.

ParticularsQuarter Ended
n++Jun. 2016Jun. 2015% Var.
Sales92.6683.3011
OPM %9.8912.74-
PBDT14.5518.68-22
PBT12.0915.01-19
NP9.489.84-4

Powered by Capital Market - Live News

Lupin allots equity shares
Dec 26,2016

Lupin announced that the Allotment Committee of Directors at its meeting held on 26 December 2016 has allotted 27020 fully paid up equity shares of Rs. 2/- each. These shares have been allotted upon exercising of options granted to the employees under Stock option plans of the Company.

In view of the above, the issued and paid up capital of the Company has been increased to Rs. 90,28,71,420 consisting 45,14,35,710 equity shares of Rs. 2/- each.

Powered by Capital Market - Live News

NTPC commissions Unit- I of 800 MW of Kudgi STTP
Dec 26,2016

NTPC announced that the Unit-1 of 800 MW of Kudgi Super Thermal Power Project of NTPC has been commissioned on 25 December 2016. This is the first 800 MW unit commissioned by NTPC.

With this the total installed capacity of NTPC on standalone basis has become 41062 MW and that of NTPC group has become 48028 MW.

Powered by Capital Market - Live News

L&T Construction secured new orders
Dec 26,2016

Larsen & Toubro announced that L&T Constructions has secured orders worth Rs 3039 crore across its various segments.

Water & effluent treatment business - Rs 1422 crore
Power transmission & distribution business - Rs 1036 crore
Heavy civil infrastructure business - Rs 359 crore
Metallurgical and material handling business - Rs 222 crore.

Powered by Capital Market - Live News

Lupin gains after receiving tentative approval from USFDA for generic drug
Dec 26,2016

The announcement was made during trading hours today, 26 December 2016.

Meanwhile, the S&P BSE Sensex was down 229.51 points or 0.88 % at 25,811.19.

On the BSE, 29,000 shares were traded on the counter so far as against the average daily volumes of 91,201 shares in the past one quarter. The stock was volatile. The stock rose as much as 1.23% at the days high of Rs 1463.15 so far during the day. The stock lost as much as 1.65% at the days low of Rs 1421.50 so far during the day.

The stock had hit a 52-week high of Rs 1911.55 on 9 February 2016 and a 52-week low of Rs 1294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 23 December 2016, declining 2.82% compared with the Sensexs 0.04% fall. The scrip had, however, outperformed the market over the past one quarter falling 2.92% as against the Sensexs 9.71% fall.

The large-cap company has equity capital of Rs 90.28 crore. Face value per share is Rs 2.

Lupin said that it has received tentative approval for its Olmesartan Medoximil Tablets, 5 mg, 20 mg and 40 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Daiichi Sankyo Daiichi Sankyo Incs Benicar Tablets, 5 mg, 20 mg and 40 mg.

Olmesatan Medoximil Tablets are indicated for the treatment of hypertension, along or with other antihypertensive agents to lower blood pressure.

Benicar Tablets had annual US sales of $1.06 billion as per the IMS MAT September 2016.

Lupins consolidated net profit rose 57.8% to Rs 662.19 crore on 31.9% rise in net sales to Rs 4211.18 crore in Q2 September 2016 over Q2 September 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredient (API) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), GI, anti-infective and NSAID space and holds global leadership position in the Anti-TB segment.

Powered by Capital Market - Live News

Divis Lab slumps over 30% in two sessions
Dec 26,2016

Meanwhile, the BSE Sensex was down 247.61 points, or 0.95%, to 25,793.09.

On the BSE, so far 15.06 lakh shares were traded in the counter, compared with average daily volumes of 60,581 shares in the past one quarter. The stock had hit a high of Rs 855 and a low of Rs 745 so far during the day.

The stock hit a record high of Rs 1,380 on 16 September 2016. The stock hit a 52-week low of Rs 745 on 26 December 2016. The stock had underperformed the market over the past 30 days till 23 December 2016, falling 24.37% compared with the 0.70% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 35.07% as against Sensexs 9.17% decline.

The large-cap company has equity capital of Rs 53.09 crore. Face value per share is Rs 2.

Shares of Divis Laboratories slumped 21.87% to Rs 866.10 on Friday, 23 December 2016, following media reports of adverse observations from the US Food and Drug Administration (USFDA) made on its Vizag facility in Andhra Pradesh. Divis Laboratories is in the process of replying to the observations raised by USFDA. Due process of reply to these observations requires Divis Laboratories to respond in detail and this is being done in time, the company said in a response to the clarification sought by the stock exchanges on the steep fall. These observations have not impacted the companys operations, the company added. USFDA inspected the Unit-2 plant from 29 November 2016 to 6 December 2016 and issued a Form 483 with five observations pertaining to breaches in data integrity, improper controls and violations of current good manufacturing practices (cGMP). The company issued the clarification after market hours on Friday, 23 December 2016.

The stock has fallen 30.18% in two trading sessions from its close of Rs 1,108.60 on Thursday, 22 December 2016.

Divis Laboratories net profit fell 24.6% to Rs 223.85 crore on 3.11% growth in net sales to Rs 991.82 crore in Q2 September 2016 over Q2 September 2015.

Divis Laboratories is primarily engaged in the manufacture of active pharmaceutical ingredients (APIs) & intermediates for generics, custom synthesis of APIs and advanced intermediates for discovery compounds for pharma giants, building blocks for peptides, building blocks for nucleotides, carotenoids and chiral ligands.

Powered by Capital Market - Live News

Ramco Systems to partner with Dubai headquartered -Western International Group
Dec 26,2016

Ramco Systems announced that Dubai-headquartered - Western International Group has chosen Ramcos full suite Human Capital Management solution to digitise its HR and payroll operations.

Powered by Capital Market - Live News

Wipro allots equity shares
Dec 26,2016

Wipro has allotted 1637 equity shares under ADS RSU Plan 2004 to the employees on 23 December 2016 pursuant to exercise of ESOPs.

Powered by Capital Market - Live News

McDonalds to open its 1st restaurant in Kollam, Kerala
Dec 26,2016

Westlife Development announced the opening of the first McDonalds restaurant in Kollam on 28 December 2016. This marks the opening of 97th restaurant for the chain in South India and 8th in the state of Kerala.

Powered by Capital Market - Live News

Asian Oilfield drops on profit booking
Dec 26,2016

Meanwhile, the S&P BSE Sensex was down 267.39 points or 1.03% at 25,773.31.

On the BSE, 46,000 shares were traded on the counter so far as against the average daily volumes of 1.38 lakh shares in the past one quarter. The stock had hit a high of Rs 115.75 and a low of Rs 108.50 so far during the day.

The stock had hit a 52-week high of Rs 124 on 14 December 2016 and a 52-week low of Rs 27.90 on 12 February 2016. It had outperformed the market over the past one month till 23 December 2016, advancing 54.64% compared with the Sensexs 0.04% fall. The scrip had also outperformed the market in past one quarter, surging 90.22% as against the Sensexs 9.17% fall.

The small-cap company has equity capital of Rs 22.32 crore. Face value per share is Rs 10.

Shares of Asian Oilfield Services surged 9.2% to settle at Rs 115.75 on Friday, 23 December 2016 after the company announced after market hours on 22 December 2016 that it has scheduled a board meeting on 27 December 2016, to consider allotment of warrants.

Meanwhile, the companys shareholders at its extraordinary general meeting (EGM) held on Friday, 23 December 2016, approved issue of up to 1.45 crore warrants of Rs 80 each in one or more tranches to a promoter entity Oilmax Energy (1 crore warrants ) and a non-resident investor Balram Chainrai (45 lakh warrants). The warrants are convertible into equity shares at an issue price of Rs 80 per warrant, at any time within 18 months from the date of allotment of the warrants.

Asian Oilfield Services reported consolidated net loss of Rs 11.12 crore in Q2 September 2016 as against net profit of Rs 4.09 crore in Q2 September 2015. Net sales declined 94.7% to Rs 3.09 crore in Q2 September 2016 over Q2 September 2015.

Asian Oilfield Services is engaged in providing geophysical, drilling and well services to customers across the Indian sub-continent.

Powered by Capital Market - Live News

102 Villages Electrified Last Week; 11,429 Villages Electrified till date under DDUGJY
Dec 26,2016

102 villages have been electrified across the country during last week (from 19thto 25thDecember 2016) under Deen Dayal Upadhyaya Gram Jyoti Yojna (DDUGJY). Out of these electrified villages, 17 villages belong to Assam, 9 to Bihar, 10 to Chhattisgarh, 29 to Jharkhand, 5 to Manipur, 30 to Odisha and 1 each to Madhya Pradesh and Rajasthan.

In view of the Prime Minister, Shri Narendra Modis address to nation, on Independence Day, Government of India has decided to electrify remaining 18,452 un-electrified villages within 1000 days i.e. by 01 May, 2018. The project has been taken on mission mode and strategy for electrification consists of squeezing the implementation schedule to 12 months and also dividing village electrification process in 12 Stage milestones with defined timelines for monitoring.

11,429 villages have been electrified till date. Out of remaining 7,023 villages, 698 villages are uninhabited. 3,775 villages are to be electrified through grid, 2,502 villages to be electrified through off-grid where grid solutions are out of reach due to geographical barriers and 48 villages are to be electrified by State Government.

Total 1654 villages were electrified during April 2015 to 14 August 2015 and after taking initiative by Government of India for taking it on mission mode, 9,775 additional villages have been electrified from 15thAugust 2015 to 25thDecember, 2016. In order to expedite the progress further, a close monitoring is being done through Gram Vidyut Abhiyanta (GVA) and various actions are also being taken on regular basis like reviewing the progress on monthly basis during the RPM meeting, sharing of list of villages which are at the stage of under energization with the state DISCOM, identifying the villages where milestone progress are delayed.

Powered by Capital Market - Live News

Panacea Biotec gains after launching fully-liquid vaccine
Dec 26,2016

The announcement was made during trading hours today, 26 December 2016.

Meanwhile, the BSE Sensex was down 229.51 points, or 0.88%, to 25,811.19.

On the BSE, so far 31,000 shares were traded in the counter, compared with average daily volumes of 16,189 shares in the past one quarter. The stock had hit a high of Rs 127 and a low of Rs 110.10 so far during the day.

The stock hit a 52-week high of Rs 155 on 25 July 2016. The stock hit a 52-week low of Rs 83.90 on 12 February 2016. The stock had outperformed the market over the past 30 days till 23 December 2016, rising 3.19% compared with the 0.70% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 7.03% as against Sensexs 9.17% decline.

The small-cap company has equity capital of Rs 6.13 crore. Face value per share is Re 1.

Panacea Biotec announced launch of Tetravalent Vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B (Hib).

Panacea Biotec is committed to protect children from vaccine-preventable diseases, Easyfour TT (DTwP-Hib), worlds first fully liquid Tetravalent vaccine launch in India will protect infant from Dn++ptheria, Tetanus, Whopping Cough, Hib-Meningitis.

Easyfour-TT is a sterile and uniform suspension, manufactured using CDAP technology with WHO pre-qualified antigens which ensures good quality, high immurogenicity and less reactogenicity. Being fully liquid, product requires, no reconstitution, therefore saves time and minimizes chance of error. Easyfour-TT comes with a legacy of being a tried and tested brand in pediatric clinical trials ensuring good ethnic response with a better reactogenicity profile.

Panacea Biotec reported net loss of Rs 11.84 crore in Q2 September 2016 as against net loss of Rs 17 crore in Q2 September 2015. Net sales declined 18.3% to Rs 131.56 crore in Q2 September 2016 over Q2 September 2015.

Panacea Biotec is one of Indias leading research based health management companies with established research, manufacturing and marketing capabilities.

Powered by Capital Market - Live News

SREI Equipment Finance to raise up to Rs 500 crore in public issue of NCDs
Dec 26,2016

SREI Infrastructure Finance announced that its subsidiary, SREI Equipment Finance is proposing a public issue of secured redeemable non-convertible debentures of face value of Rs 1000 each amounting up to Rs 500 crore. The issue opens on 03 January 2017 and will close on 20 January 2017.

Powered by Capital Market - Live News

Rabi Crops Sowing Crosess 554 Lakh Hactare
Dec 26,2016

As per preliminary reports received from the States, the total area sown under Rabi crops as on 23rd December, 2016 stands at 554.91 lakh hectares as compared to 523.40 lakh hectare this time in 2015.

Wheat has been sown/transplanted in 278.62 lakh hectares, rice in 9.33 lakh hectares, pulses in 138.25 lakh hectares, coarse cereals in 50.63 lakh hectares and area sown under oilseeds is 78.08 lakh hectares.

The area sown so far and that sown during last year this time is as follows:

Lakh hectare 

CropArea sown in 2016-17Area sown in 2015-16Wheat278.62259.37Rice9.3313.27Pulses138.25125.73Coarse Cereals50.6354.91Oilseeds78.0870.12Total554.91523.40

Powered by Capital Market - Live News

CII-Triveni Water Institute inks MoU with the Water Research Center, Tel Aviv University, on Improving Indian Water Scenario across States and Regions
Dec 26,2016

CII-Triveni Water Institute, CIIs Center of Excellence on Water and the Water Research Center, Tel Aviv University, Israel, entered into Memorandum of Understanding, during the 9th India-Israel Forum. The MoU was signed by Mr Chandrajit Banerjee, Director General, CII, and Prof Joseph Klafter, President, Tel Aviv University.

The MoU enhances cooperation of the two countries on planning, designing, and implementing new and innovative tools and technologies that improve management of water in India. It identifies opportunities and geographical areas where WRC-TAU and CII-TWI will pool expertise and derive workable, scalable solutions in the water sector in India, for the benefit of the community at large. This includes technology, management, policy reforms and advance tools and techniques.

It covers various sectors namely, irrigation, industry, domestic water use, wastewater management, municipal sewage recycle, improving water use efficiency, training and capacity building, and most importantly implementing of strategies in drought prone areas of India. CII-Triveni Water Institute and Water Research Center, TAU together will work towards improving the water scenario across several states and regions of India.

Prof Klafter, TAU, mentioned that learnings from Israel, customized and applied to water sector in India will further strengthen the bilateral ties between the two countries. Political will and scientific considerations will lead to successful applications. In situ treatment technologies will also have a key role to play on a decentralized basis.

Mr Nikhil Sawhney, Member, Advisory Board, CII-Triveni Water Institute, and Managing Director, Triveni Turbine, mentioned that models of Public Private Partnerships, Awareness Generation, Policy reforms and Pricing that were applied and helped convert a desert country like Israel into Water surplus country will be further studied for adoption in India. The MoU would help advancing these.

Mr Chandrajit Banerjee, Director General, CII, said that the MoU opens doors to new state-of-the-art techniques and technologies that will be customized and implemented. He mentioned that combination of Intelligent Policy, Advanced Technology, and Stakeholder Participation will certainly bring about the much desired change in the sector. CIIs WATSCAN, Water Scanning Tool, will be used and further strengthened for selection, and implementation of Water management strategies in the country.

Powered by Capital Market - Live News

Panacea Biotec launches Tetravalent Vaccine Easyfour-TT
Dec 26,2016

Panacea Biotec announced the launch of Tetravalent Vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and Haemophilus Influenza Type B(Hib).

Easyfour-TT, worlds first fully liquid Tetravalent vaccine launched in India, will protect infant from Diptheria, Tetanus, Whopping Cough and Hib-Meningitis.

Powered by Capital Market - Live News